Thursday, July 11, 2024



Leukemia Treatment Advances with FDA Approval of Blincyto by Amgen for B-ALL

Leukemia treatment has advanced with the Food and Drug Administration's (FDA) approval of Amgen’s Blincyto (blinatumomab) for CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic...

FDA Approves Amgen’s IMDELLTRA™ for Lung Cancer, Offering New Hope for Patients

Amgen's groundbreaking IMDELLTRA™ (tarlatamab-dlle) therapy has received the Food and Drug Administration (FDA) approval for the treatment of extensive-stage small cell lung cancer (ES-SCLC)...

Competition Heats Up for First-Line KRAS Inhibitor in Lung Cancer Treatment

In the relentless quest to combat KRAS-mutated non-small cell lung cancer (NSCLC), Amgen's Lumakras and Mirati's Krazati have secured approval for second-line treatment. However,...

Latest news